{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
ORG 37684 is a selective full agonist of 5-hydroxytryptamine receptor 5-HT2 family with a high selectivity for 5-HT2C in comparison with 5-HT2B and 5-HT2A receptors. It was studied for treatment of depression, but that investigations were discontinued. On animal studies ORG 37684 possessed hypophagic effect, which was exclusively mediated by activation of 5-HT2C receptors. Thus, this compound can be further investigated in using for weight loss.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CP 226269 is a selective dopamine D4 agonist. This compound was developed by Pfizer for Neuroscience research. CP226269 showed a significant enhancement in the 5-trial inhibitory avoidance model.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
![Structure of 4-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol](/img/cf1b0516-0b22-ab71-76e9-357063dc24a4.svg?size=200&context=nsyfptiosu)
